Skip to main content
Premium Trial:

Request an Annual Quote

Expedeon, Protein Discovery to Merge

NEW YORK (GenomeWeb News) – Expedeon and Protein Discovery today announced that they have signed a merger agreement.

Under the terms of the deal, the new company will keep the Expedeon name and remain headquartered in Cambridge, UK. Heikki Lanckriet, founder and CEO of Expedeon, will be the CEO of the new firm. Chuck Witkowski, founder and CEO of Protein Discovery, will join Expedeon's board of directors, the firms said.

Financial terms of the deal were not disclosed.

In addition to its Cambridge location, Expedeon has offices in San Diego. Its products include RunBlue electrophoresis precast gels, InstantBlue protein stain, and Nvoy protein stabilization products.

Protein Discovery, headquartered in Knoxville, Tenn., develops products for protein analysis. Its flagship product is the GelFree 8100 Fractionation System for partitioning complex protein mixtures into user-selectable, liquid-phase molecular weight fractions. It also provides consumables for the enhancement of data.

"By combining our businesses, we have an opportunity to create substantial value for our customers, shareholders, and other key stakeholders as we extend our innovative solutions to customers around the world," Witkowski said in a statement.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.